Lechleider Robert 4

What Happened
Robert Lechleider, Chief Medical Officer of Immunome (IMNM), exercised 55,000 stock options on 2026-06-25 (acquiring shares at $8.73 per share for $480,150) and sold those 55,000 shares the same day in two open-market transactions. The sales generated total gross proceeds of $1,091,662 (40,580 shares at a weighted $19.56 for $793,745; 14,420 shares at a weighted $20.66 for $297,917). The filing also reports the related derivative instrument as disposed at $0.00 (reflecting conversion/exercise).

Key Details

• Transaction date: 2026-06-25; Form 4 filed 2026-06-29 (appears timely).
• Option exercise: 55,000 shares @ $8.73 = $480,150 (code M).
• Open-market sales: 40,580 shares @ weighted $19.56 = $793,745 (code S); 14,420 shares @ weighted $20.66 = $297,917 (code S). Total sales proceeds = $1,091,662.
• Reporting of derivative disposition: 55,000 shares listed as disposed at $0.00 (reflects exercise/conversion of the option).
• Footnotes: Sales were made under a Rule 10b5-1 trading plan adopted March 26, 2026 (F1). Price ranges for the two sales: $19.27–$20.255 (F2) and $20.275–$21.02 (F3). Vesting note: option vested 25% on Oct 16, 2024, with remaining shares vesting monthly over three years (F4).
• Shares owned after the transactions: not specified in the provided filing details.

Context

• This was an option exercise followed by same-day open-market sales of the acquired shares (effectively a cashless exercise/sale). Such transactions commonly reflect liquidity actions rather than an added equity stake.
• The use of a 10b5-1 plan means the sales were pre-established under a trading plan adopted March 26, 2026.
• The filing shows both the exercise (acquisition) and the subsequent sales; it does not by itself indicate the insider’s view of the company’s prospects.